Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

pack pharmaceuticals, llc - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae , and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefac

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

carlsbad technology, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae , and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefac

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

carlsbad technology, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclo

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml - granules for oral suspension - 250 mg/5ml - active: cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg; cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg - capsule - 250 mg - active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg - capsule - 500 mg - active: cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin and ski

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets usp and other antibacterial drugs, cefaclor extended-release tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have not been established. when administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the desig

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

rebel distributors corp - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is gene

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cef